Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade

Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F210-F218. doi: 10.1152/ajprenal.00389.2017. Epub 2017 Oct 11.


The intrarenal renin angiotensin system (RAS) is activated in polycystic kidney disease. We have recently shown in the Pkd1 mouse that Gen 2 antisense oligonucleotide (ASO), which suppresses angiotensinogen (Agt) synthesis, is efficacious in slowing kidney cyst formation compared with lisinopril. The aim of this current study was to determine 1) if unilateral nephrectomy accelerates cystogenesis in Pkd1 mice (as previously shown in cilia knockout mice) and 2) whether Agt ASO can slow the progression in this accelerated cystic mouse model. Adult Pkd1 conditional floxed allele mice expressing cre were administered tamoxifen, resulting in global knockout of Pkd1. Three weeks after tamoxifen injection, mice underwent left unilateral nephrectomy. Mice were then treated with Agt ASO (75 mg/kg per week) or aliskiren (20 mg/kg per day)+Agt ASO or control for 8 wk. Unilateral nephrectomy accelerated kidney cyst formation compared with nonnephrectomized mice. Both Agt ASO and Aliskiren+Agt ASO treatments significantly reduced plasma and urinary Agt levels. Blood pressure was lowest in Aliskiren+Agt ASO mice among all treatment groups, and the control group had the highest blood pressure. All mice developed significant kidney cysts at 8 wk after nephrectomy, but Agt ASO and Aliskiren+Agt ASO groups had fewer kidney cysts than controls. Renal pAkt, pS6 levels, and apoptosis were significantly suppressed in those receiving Agt ASO compared with controls. These results indicate that suppressing Agt using an ASO slowed the progression of accelerated cystic kidney disease induced by unilateral nephrectomy in Pkd1 mice by suppressing intrarenal RAS, mammalian target of rapamycin pathway, and cell proliferation.

Keywords: ADPKD, angiotensinogen; oligonucleotide; polycystic kidney disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology*
  • Angiotensinogen / genetics
  • Angiotensinogen / metabolism*
  • Animals
  • Apoptosis / drug effects
  • Cell Proliferation / drug effects
  • Disease Models, Animal
  • Disease Progression
  • ErbB Receptors / metabolism
  • Female
  • Fumarates / pharmacology*
  • Genetic Predisposition to Disease
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Male
  • Mice, Knockout
  • Nephrectomy
  • Oligonucleotides, Antisense / genetics
  • Oligonucleotides, Antisense / metabolism
  • Phenotype
  • Polycystic Kidney, Autosomal Dominant / genetics
  • Polycystic Kidney, Autosomal Dominant / metabolism
  • Polycystic Kidney, Autosomal Dominant / pathology
  • Polycystic Kidney, Autosomal Dominant / prevention & control*
  • Renin / antagonists & inhibitors*
  • Renin / metabolism
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / genetics
  • TOR Serine-Threonine Kinases / metabolism
  • TRPP Cation Channels / deficiency
  • TRPP Cation Channels / genetics
  • TRPP Cation Channels / metabolism*
  • Time Factors


  • Agt protein, mouse
  • Amides
  • Fumarates
  • Oligonucleotides, Antisense
  • TRPP Cation Channels
  • polycystic kidney disease 1 protein
  • Angiotensinogen
  • aliskiren
  • mTOR protein, mouse
  • EGFR protein, mouse
  • ErbB Receptors
  • TOR Serine-Threonine Kinases
  • Renin